RecruitingNCT06526689

Lung Innate Immunity and Microbiome After Tuberculosis Exposure

Investigating the Impact of the Pulmonary Innate Immune Response and Microbiome After Exposure to Mycobacterium Tuberculosis

Sponsor

University of Oxford

Enrollment

50 participants

Start Date

Aug 15, 2024

Study Type

OBSERVATIONAL

Conditions

Tuberculosis Latent Tuberculosis

Summary

To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposure

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with latent tuberculosis and tuberculosis. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(3)

Churchill Hospital

Oxford, Oxfordshire, United Kingdom

Centre for Clinical Vaccinology and Tropical Medicine

Oxford, Oxon, United Kingdom

Grove Building, Royal Free NHS Foundation Trust

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06526689

Related Trials

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

NCT062818341 location

A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)

NCT0602214666 locations